On August 10, 2026, a trial update was recorded for a study involving bivalirudin, an approved compound. The trial, titled "Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System," is registered under identifier NCT06080074. The study is listed as Phase 2 and is currently in the recruiting status. According to the registry entry, the trial is multicenter in design and focuses on the use of extracorporeal membrane oxygenation, or ECMO, in pediatric patients experiencing severe cardiac failure. The Cardiohelp System is named as part of the study protocol. No outcome data or results have been reported as part of this update. The trial's current status reflects only that participant enrollment is ongoing as of the date listed. No efficacy or safety conclusions can be drawn from a recruiting status alone. Further details on trial design, eligibility, and endpoints are available through the official registry listing. For more background on bivalirudin, readers can consult the compound overview.</body_markdown>
<parameter name="sources">["https://clinicaltrials.gov/study/NCT06080074"]